Sitryx Therapeutics announced positive Phase 1a trial results for SYX-5219, an oral PKM2 modulator targeting atopic dermatitis. The trial in healthy volunteers showed the drug was safe, well tolerated, and demonstrated immune system modulation by reducing a key inflammation biomarker. This supports SYX-5219's potential as a disease-modifying oral therapy for atopic dermatitis. A Phase 1b trial in patients with severe atopic dermatitis is ongoing, with data expected by the end of 2026.
Salesforce announced it will acquire Listen Labs, a company specializing in AI-driven customer research and human simulation. Listen Labs' technology accelerates customer insight processes from months to days by using AI agents that conduct studies a...
Sun Life U.S. has integrated its Health Navigator service with disability insurance to enhance employer health plans by offering personalized care navigation. This service helps employees facing serious health conditions find the right specialists, a...
Securitize, a leading tokenization platform managing over $4 billion in assets, has joined the Open USD (OUSD) stablecoin network as a partner. This partnership aims to integrate Securitize's tokenized assets with OUSD's multi-blockchain stablecoin, ...
Amazon's AI infrastructure capital expenditure is projected to reach $220 billion by 2026, supported by substantial multi-year commitments from Anthropic and OpenAI totaling over $225 billion in AWS and Trainium capacity. AWS reported a 37% year-over...
PEPE cryptocurrency price remains above $0.000004 as its September rally cools, showing mixed technical signals. Daily indicators suggest a short-term bearish pattern with key support at $0.0000041 and a potential drop to $0.0000030 if that support b...
